Entrepreneur UK's London 100: Unai
Unai is a UK-crafted sparkling drink that harnesses the wellness-boosting benefits of functional mushrooms, offering a refreshing approach to mindful living.
The brand is centered around themes of grounding and being present, promoting a lifestyle rooted in balance and intention.
Owned by London-based Matthew Glover, Unai is part of a growing movement that blends natural ingredients with modern wellness, providing consumers with a functional beverage that supports both body and mind.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Boys and girls should be taught about periods together in school, academics say
Girls and boys should be taught about periods in mixed-sex groups in school to improve their understanding of menstruation, researchers have said. A study by University College London (UCL) academics has suggested that pupils in schools are being given insufficient information around periods. For many pupils they are given just two lessons about periods in their whole school career – one in primary and one in secondary, researchers have said. They have called for lessons on menstruation in schools to be much 'more comprehensive'. Since September 2020, relationships and sex education has been compulsory in secondary schools in England, while relationships education has been compulsory in primary schools. Professor Joyce Harper, from UCL Institute for Women's Health, said: 'Educating pupils about periods may now be compulsory in schools in England and Wales, but we know that for many of them that still only amounts to two lessons in their entire school career.' The researchers suggested that periods should be taught among mixed-sex groups, as well as single-sex groups, which some schools do not currently do. Prof Harper said: 'Our focus groups were also of the view that boys need to be part of that education. 'It was agreed that classes should not be segregated by gender, believing mixed sessions are crucial for boys' education. 'Although some saw value in single-sex classes to allow students to speak more freely, they still felt mixed sessions were essential to improve overall understanding. 'They suggested this could help boys understand and support their friends and future partners through menopause.' Overall, 55 women took part in the study divided into two groups based on age (18 to 25 and 26 to 40) and five focus groups were conducted for each group. They were recruited via social media, and many of the women were educated before the topic on menstruation became mandatory in English schools. The academics said menstruation is 'highly stigmatised' and a 'lack of education' about difficult periods restricts individuals from seeking help. Co-author Caroline Musulin, from UCL Institute for Women's Health, said: 'Many women endure menstrual problems longer than they should due to the inability to speak openly about uncertainties, fears of being dismissed by healthcare professionals, the view that it's 'just' a painful period or feelings of shame. 'Stigma, secrecy, and the expectation to 'cope' with painful periods contribute to the systemic dismissal of menstrual discomfort.' The latest statutory Government guidance on relationships, sex and health education (RSHE) in schools says pupils should be taught about menstruation in primary and secondary school. The guidance, which was published last month, says pupils should learn the facts about the menstrual cycle, including physical and emotional changes, by the end of primary school to help them understand what to expect. By the end of secondary school, pupils should learn about menstrual and gynaecological health – including period problems such as premenstrual syndrome, heavy menstrual bleeding, endometriosis and polycystic ovary syndrome – as well as menopause, the guidance adds. The latest Department for Education (DfE) guidance says: 'RSE lessons should ensure that both boys and girls have opportunities to practise respectful communication and understand experiences which are different from their own, including menstruation and menopause.' Schools in England will have to follow the statutory RSHE guidance from September 2026. Sarah Hannafin, head of policy for school leaders' union NAHT, said: 'Teaching about periods is a vital part of health education for all pupils. 'Although many schools may separate classes to create a safe space for discussions on topics like this, mixed-sex groups should also be planned as it is vital that pupils understand others' experiences. 'Schools need freely available high-quality resources to support them to do this. 'Education about periods needs more than a single lesson but the curriculum in both primary and secondary schools is overcrowded and the new RSHE guidance has added a lot of new content without any additional time being created.' Pepe Di'Iasio, general secretary of the Association of School and College Leaders, said: 'We fully support the need for boys and girls to be taught about menstruation in a comprehensive manner which goes beyond biological facts and covers the wider effects on wellbeing. 'It is essential to be able to discuss this topic openly without misinformation or embarrassment. 'While it is covered in the RSHE curriculum we would welcome consideration of how teaching of this topic might be strengthened.' A DfE spokesperson said: 'Understanding menstruation is an important part of growing up, which is why we have brought in a new relationships, sex and health education curriculum to take effect next year, with clear guidance that pupils should be taught about both physical and emotional changes, as well as topics from endometriosis to heavy menstrual bleeding. 'As part of our plan for change, we're providing teachers with new resources to help them run great lessons on these issues, tackle stigma head-on and support every child to achieve and thrive.'
Forbes
25 minutes ago
- Forbes
NFL Great J.J. Watt Enjoys Honeymoon Period As Espanyol Shareholder
Dawn is breaking at Espanyol in Spain's La Liga. Fans of the Parakeets, a team less followed and with more grounded aims than local colossus Barcelona, hope it won't be a false one. Meanwhile, ex-defensive end J.J. Watt has a role to play. Now turning his attention towards being an NFL game analyst this coming season at CBS Sports, dissecting a game he knows inside out, Watt got a first taste of another new role—in soccer—last weekend. The 36-year-old looked on from the stands, fists pumping, as Espanyol fought back to beat Atlético Madrid in the surprise result from the opening matchday. The former Houston Texans player is a shareholder of Velocity Sports Limited (VSL), an investment branch of ALK Capital, which is led by U.S. managing partner Alan Pace. VSL acquired Espanyol from the Rastar Group, controlled by the Chinese businessman Chen Yensheng, for a reported €130 million ($152 million) in July (though Rastar retains some input). VSL also controls Premier League club Burnley. Much optimism surrounds Watt's arrival. El Mundo has gone as far as calling him Espanyol's new idol (Spanish). Much of that is down to the American ingratiating himself after saying a couple of phrases in Catalan, enjoying a beer with supporters outside the stadium, and getting behind the players inside it. Watt says he can't return there until February because of work commitments on Sundays, yet it's already a shift from the previous owners, who were rarely present and oversaw two relegations despite initially eyeing a place in the Champions League. Is The Future Bright For Espanyol? There's a peculiarity with ownership in soccer today. Many, even those who attend every fixture or know their side's history back to front, will understand that a foreign executive arriving on the scene doesn't. But if they stay involved, not least by investing in the squad, that's good enough. Very much the face of VSL in Espanyol right now, Watt has made a good impression. Then again, it's the honeymoon period, and at a club whose main target will still be avoiding demotion to the second division. How Espanyol does under U.S. guidance in the long term is what matters. It's worth noting that while Burnley and Espanyol are part of the same investment group, and therefore could be deemed part of the growing multi-club ownership model, the Spanish entity stressed that each will remain independent. Still, when interests are diversified, does Espanyol become the priority, or is that consolidating Burnley's place in the Premier League? Then, there's a cultural angle; Watt may have donned the blue and white scarf, but VSL is adapting to a different division in a different country, and everything that entails. U.S. Links To Spanish Soccer Are Tightening Of course, U.S. majority ownership in European soccer—Spain in this instance—is nothing new. Notably, top-tier Mallorca has former tennis player Andy Kohlberg at the top, while Leganés—relegated to the Segunda in 2024/25—is led by Blue Crow Sports CEO Jeff Luhnow. All the while, the Spanish soccer federation (RFEF) has approved controversial plans to host a first La Liga game on U.S. soil (Miami) this December. As the games and seasons progress, with Espanyol set on taking more scalps after the fast start against Atlético, it will become clearer whether the Catalans benefit from their end of the deal. At least the initial signs are promising.
Yahoo
an hour ago
- Yahoo
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
